Table 5.
Summary of statistical analyses in individuals with functional variants in relevant CYPs
| Clinical variable | All patients (N = 155) | Clozapine treated patients (N = 68) | Patients treated with CYP2D6 substrates (N = 41) | |||
|---|---|---|---|---|---|---|
| PharmG+ (N = 79) | PharmG− (N = 76) | PharmG+ (N = 30) | PharmG− (N = 38) | PharmG+ (N = 21) | PharmG− (N = 20) | |
| Difference in PANSS average | 26.88 + 1.4 | 25.92 + 1.3 | 30.10 + 3 | 24.74 + 2 | 26.58 + 3.5 | 28.63 + 3.7 |
| Model χ2 (p value) | 1.68 (0.89) | 5.19 (0.27) | 12.88 (0.03) | |||
| PI Wald (p value) | 0.16 (0.69) | 1.78 (0.18) | 1.03 (0.31) | |||
| Difference in UKU scores | 4.20 ± 0.76 | 3.01 ± 0.66 | 4.24 ± 1.39 | 3.08 ± 1.25 | 6.92 ± 2.09 | 1.27 ± 1.78 |
| Model χ2 (p value) | 8.80 (0.12) | 3 (0.56) | 8.20 (0.15) | |||
| PI Wald (p value) | 1.23 (0.27) | 0.02 (0.89) | 5.56 (0.02) | |||
| Difference in psychic SE | 2.40 ± 0.41 | 1.21 ± 0.37 | 2.14 ± 0.82 | 1.42 ± 0.70 | 2.50 ± 1.14 | 0.53 ± 0.77 |
| Model χ2 (p value) | 10.90 (0.05) | 1.20 (0.88) | 10.83 (0.06) | |||
| PI Wald (p value) | 3.30 (0.07) | 0.14 (0.71) | 3.96 (0.05) | |||
| Difference in neurological SE | 0.99 ± 0.24 | 1.08 ± 0.26 | 1.24 ± 0.40 | 0.67 ± 0.67 | 1.67 ± 0.64 | 0.53 ± 0.76 |
| Model χ2 (p value) | 11.27 (0.05) | 15.91 (0.003) | 3.63 (0.60) | |||
| PI Wald (p value) | 0.01 (0.91) | 0.03 (0.87) | 1.67 (0.20) | |||
| Difference autonomic SE | 0.31 ± 0.29 | 0.20 ± 0.13 | 0.07 ± 0.64 | 0.75 ± 0.41 | 1.33 ± 0.91 | 0.13 ± 0.13 |
| Model χ2 (p value) | 3.04 (0.69) | 2.14 (0.71) | 5.13 (0.40) | |||
| PI Wald (p value) | 0.22 (0.64) | 0.66 (0.42) | 1.29 (0.26) | |||
| Difference in other side effects | 0.59 ± 0.28 | 0.45 ± 0.29 | 0.86 ± 0.39 | 0.25 ± 0.74 | 1.08 ± 0.57 | −0.3 ± 0.41 |
| Model χ2 (p value) | 7.39 (0.19) | 6.20 (0.19) | 7.99 (0.16) | |||
| PI Wald (p value) | 0.10 (0.75) | 0.08 (0.78) | 6.19 (0.01) | |||
PI pharmacogenetic intervention, SE side effects